← Every applicant
Qilu Pharm Hainan FDA Approvals
14 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| DIFELIKEFALIN ACETATENew drugAug 31, 2026SOLUTION, INTRAVENOUS |
| SUGAMMADEX SODIUMNew drugJul 28, 2026SOLUTION, INTRAVENOUS |
| CARBOPLATINNew drugFeb 4, 2026INJECTABLE, INTRAVENOUS |
| DOXORUBICIN HYDROCHLORIDENew drugFeb 3, 2026INJECTABLE, LIPOSOMAL, INJECTION |
| NICARDIPINE HYDROCHLORIDENew drugOct 28, 2025INJECTABLE, INJECTION |
| POSACONAZOLENew drugApr 23, 2025TABLET, DELAYED RELEASE, ORAL |
| MICAFUNGIN SODIUMNew drugApr 3, 2025INJECTABLE, INTRAVENOUS |
| BUMETANIDENew drugSep 19, 2024INJECTABLE, INJECTION |
| GEFITINIBNew drugFeb 13, 2023TABLET, ORAL |
| IMATINIB MESYLATENew drugJun 21, 2022TABLET, ORAL |
| PEMETREXED DISODIUMNew drugMay 25, 2022POWDER, INTRAVENOUS |
| BORTEZOMIBNew drugMay 2, 2022INJECTABLE, INTRAVENOUS, SUBCUTANEOUS |
| DAPTOMYCINNew drugAug 24, 2021POWDER, INTRAVENOUS |
| DECITABINENew drugApr 12, 2021INJECTABLE, INTRAVENOUS |